Uloga farmaceuta u zbrinjavanju pacijenta sa poremećajem rada tiroidne žlezde

  • Ana Homšek Univerzitet u Beogradu – Farmaceutski fakultet, Katedra za farmakokinetiku i kliničku farmaciju
  • Maša Roganović Univerzitet u Beogradu – Farmaceutski fakultet, Katedra za farmakokinetiku i kliničku farmaciju
  • Milena Kovačević Univerzitet u Beogradu – Farmaceutski fakultet, Katedra za farmakokinetiku i kliničku farmaciju
  • Marija Jovanović
DOI: https://doi.org/10.5937/arhfarm72-39948
Ključne reči: hipotireoidizam, hipertireoidizam, farmaceutska zdravstvena zaštita, savetovanje pacijenata

Sažetak


Poremećaj funkcije tiroidne žlezde spada u najčešće endokrine poremećaje, posebno u ženskoj populaciji. Ukoliko se poremećaj ne ustanovi na vreme i ne leči adekvatno, kvalitet života pacijenta može biti narušen i može doći do dodatnih zdravstvenih problema, s obzirom na ključne uloge koje tireoidni hormoni imaju u organizmu. Stoga je neophodno podići svest o važnosti prepoznavanja simptoma koji ukazuju na potencijalni problem sa štitnom žlezdom, kao i moguće uzroke. Kod pacijenata koji su na terapiji levotiroksinom (hipotireoidizam) ili tiamazolom, karbimazolom ili propiltiouracilom  (hipertireoidizam), potrebno je ukazati na značaj pravilne i redovne upotrebe lekova, uz sprovođenje pratećih nefarmakoloških mera, i ukazati na potencijal za pojavu neželjenih reakcija i interakcija sa drugim lekovima/hranom. Značajnu ulogu u navedenim aktivnostima bi trebalo da ima farmaceut, kao najdostupniji član zdravstvenog tima, koji može uputiti pacijenta lekaru radi postavljanje dijagnoze, pratiti efikasnost i bezbednost terapije, i pružiti pacijentu adekvatno savetovanje.

Reference

1. Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99(3):923-31.

2. Kalhan A, Page MD. Thyroid and parathyroid disorders. In: Whittlesea C, Hadson K, editors. Clinical Pharmacy and Therapeutics (6th edition). London: Elsevier; 2019; p. 744-761.

3. Wiffen P, Mitchell M, Snelling M, Stoner N. Thyroid disorders. In: Oxford Handbook of Clinical Pharmacy (3rd edition). Oxford: Oxford University Press; 2017; p. 495-503.

4. Martin CM. Thyroid dysfunction and the elderly patient: a primer for pharmacists. Consult Pharm. 2012;27(10):682-8.

5. Chiovato L, Magri F, Carle A. Hypothyroidism in context: where we've been and where we're going. Adv Ther. 2019;36(Suppl 2):47-58.

6. Chaker L, Razvi S, Bensenor IM, Azizi F, Pearce EN, Peeters RP. Hypothyroidism. Nat Rev Dis Primers. 2022;8(1):30.

7. Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, et al. Graves' disease. Nat Rev Dis Primers. 2020;6(1):52.

8. Hanley P, Lord K, Bauer AJ. Thyroid disorders in children and adolescents: a review. JAMA Pediatr. 2016;170(10):1008-1019.

9. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533-43.

10. McRobbie D, Webb D, Davies G. Clinical pharmacy practice. In: Whittlesea C, Hadson K, editors. Clinical Pharmacy and Therapeutics (6th edition). London: Elsevier; 2019; p. 2-13.

11. Wiffen P, Mitchell M, Snelling M, Stoner N. Concept and core elements of pharmaceutical care. In: Oxford Handbook of Clinical Pharmacy (3rd edition). Oxford: Oxford University Press; 2017; p. 34-37.

12. Pharmaceutical Care Network Europe Association [Internet]. Pharmaceutical Care Network Europe Classification for Drug Related Problem V9.1; 2020 [cited 2022 August 15]. Available from: https://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf.

13. Berenguer B, La Casa C, de la Matta MJ, Martin-Calero MJ. Pharmaceutical care: past, present and future. Curr Pharm Des. 2004;10(31):3931-46.

14. Dong BJ. Pharmacist involvement in a thyroid clinic. Am J Hosp Pharm. 1990;47(2):356-61.

15. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751.

16. Colucci P, Yue CS, Ducharme M, Benvenga S. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol. 2013;9(1):40-47.

17. Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA Guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215-28.

18. Duntas LH, Jonklaas J. Levothyroxine dose adjustment to optimise therapy throughout a patient's lifetime. Adv Ther. 2019;36(Suppl 2):30-46.

19. FDA levothyroxine [Internet]. Food and Drug Administration prescribing information for EUTHYROX® (levothyroxine sodium) tablets [cited 2022 July 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021292s004,021292s005,021292s006lbl.pdf.

20. SmPC levothyroxine [Internet]. Summary of Product Characteristic for levothyroxine (eMC) [cited 2022 July 25]. Available from: https://www.medicines.org.uk/emc/product/5806/.

21. Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2019;40(1):118-136.

22. Schaffler A. Hormone replacement after thyroid and parathyroid surgery. Dtsch Arztebl Int. 2010;107(47):827-34.

23. Benvenga S, Carle A. Levothyroxine formulations: pharmacological and clinical implications of generic substitution. Adv Ther. 2019;36(Suppl 2):59-71.

24. Holmes DR Jr, Becker JA, Granger CB, Limacher MC, Page RL 2nd, Sila C, et al. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. J Am Coll Cardiol. 2011;58(12):1287-307.

25. Soldin OP, Soldin SJ, Vinks AA, Younis I, Landy HJ. Longitudinal comparison of thyroxine pharmacokinetics between pregnant and nonpregnant women: a stable isotope study. Ther Drug Monit. 2010;32(6):767-73.

26. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J. 2014;3(2):76-94.

27. Haddad HM. Rates of I 131-labeled thyroxine metabolism in euthyroid children. J Clin Invest. 1960;39:1590-4.

28. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005;90(1):124-7.

29. Ling H, Patel A, Park J, Bhave VS. Thyroid hormones, iodine and iodides, and antithyroid drugs. In: Ray SD, editor. Side Effects of Drugs Annual. Amsterdam: Elsevier; 2019; p. 481-492.

30. Abdi H, Amouzegar A, Azizi F. Antithyroid Drugs. Iran J Pharm Res. 2019;18(Suppl1):1-12.

31. SmPC thiamazole [Internet]. Summary of Product Characteristic for thiamazole (ALIMS) [cited 2022 August 10]. Available from: https://www.alims.gov.rs/doc_file/lekovi/smpc/515-01-04554-18-001.pdf

32. SmPC propylthiouracil [Internet]. Summary of Product Characteristic for propylthiouracil (ALIMS) [cited 2022 August 10]. Available from: https://www.alims.gov.rs/doc_file/lekovi/smpc/515-01-02069-18-001.pdf.

33. Liu J, Fu J, Xu Y, Wang G. Antithyroid drug therapy for Graves' disease and implications for recurrence. Int J Endocrinol. 2017;2017:3813540.

34. SmPC carbimazole [Internet]. Summary of Product Characteristic for carbimazole (eMC) [cited 2022 August 10]. Available from: https://www.medicines.org.uk/emc/product/10328.

35. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.

36. Kampmann JP, Hansen JM. Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet. 1981;6(6):401-28.

37. Azizi F, Abdi H, Amouzegar A, Habibi Moeini AS. Long-term thionamide antithyroid treatment of Graves' disease. Best Pract Res Clin Endocrinol Metab. 2022:101631. doi: 10.1016/j.beem.2022.101631.

38. Benker G, Reinwein D. Pharmacokinetics of antithyroid drugs. Klin Wochenschr. 1982;60(11):531-9.

39. Amisha F, Rehman A. Propylthiouracil (PTU) [Internet]. StatPearls [cited 2022 August 10]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549828/.

40. Skellern GG, Knight BI, Otter M, Low CK, Alexander WD. The pharmacokinetics of methimazole in pregnant patients after oral administration of carbimazole. Br J Clin Pharmacol. 1980;9(2):145-7.

41. E-Lactancia [Internet]. Association for Promotion and Cultural and Scientific Research of Breastfeeding, Spain [cited 2022 August 15]. Available from: www.e-lactancia.org.

42. Crooks J, O'Malley K, Stevenson IH. Pharmacokinetics in the elderly. Clin Pharmacokinet. 1976;1(4):280-96.

43. Azizi F. The safety and efficacy of antithyroid drugs. Expert Opin Drug Saf. 2006;5(1):107-16.

44. Tan S, Chen L, Jin L, Fu X. The efficiency and safety of methimazole and propylthiouracil in hyperthyroidism: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021;100(30):e26707.

45. Singh G, Correa R. Methimazole [Internet]. StatPearls [cited 2022 August 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545223/.

46. British Thyroid Foundation [Internet]. Thyroid and diet factsheet [cited 2022 August 15]. Available from: https://www.btf-thyroid.org/thyroid-and-diet-factsheet.

47. Danailova Y, Velikova T, Nikolaev G, Mitova Z, Shinkov A, Gagov H, et al. Nutritional management of thyroiditis of Hashimoto. Int J Mol Sci. 2022;23(9):5144. doi: 10.3390/ijms23095144.

48. Ihnatowicz P, Drywien M, Wator P, Wojsiat J. The importance of nutritional factors and dietary management of Hashimoto's thyroiditis. Ann Agric Environ Med. 2020;27(2):184-193.

49. Liontiris MI, Mazokopakis EE. A concise review of Hashimoto thyroiditis (HT) and the importance of iodine, selenium, vitamin D and gluten on the autoimmunity and dietary management of HT patients.Points that need more investigation. Hell J Nucl Med. 2017;20(1):51-56.

50. Pirola I, Rotondi M, Cristiano A, Maffezzoni F, Pasquali D, Marini F, et al. Selenium supplementation in patients with subclinical hypothyroidism affected by autoimmune thyroiditis: Results of the SETI study. Endocrinol Diabetes Nutr (Engl Ed). 2020;67(1):28-35.

Objavljeno
2022/10/31
Broj časopisa
Vol. 72 Br. Notebook 5 (2022): Arhiv za farmaciju
Rubrika
Stručni rad
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).